The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Top Cited Papers
Open Access
- 30 March 2015
- journal article
- review article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 37 (4), 764-782
- https://doi.org/10.1016/j.clinthera.2015.02.018
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- A new therapeutic strategy for malaria: targeting T cell exhaustionNature Immunology, 2012
- Overall survival and PD‐L1 expression in metastasized malignant melanomaCancer, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Structures of PD-1 with its ligands: Sideways and dancing cheek to cheekProceedings of the National Academy of Sciences of the United States of America, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune diseaseNature, 2003